11/15
05:29 am
csci
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) [Yahoo! Finance]
Low
Report
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) [Yahoo! Finance]
11/12
07:30 am
csci
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
High
Report
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
10/8
07:30 am
csci
COSCIENS Biopharma Announces Change to Board of Directors
Neutral
Report
COSCIENS Biopharma Announces Change to Board of Directors
10/1
05:42 pm
csci
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director [Yahoo! Finance]
Low
Report
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director [Yahoo! Finance]
10/1
05:39 pm
csci
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director [Financial Post (Toronto, Ontario, Canada)]
Low
Report
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director [Financial Post (Toronto, Ontario, Canada)]
10/1
05:30 pm
csci
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
Low
Report
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
9/23
07:36 am
csci
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs [Financial Post (Toronto, Ontario, Canada)]
9/23
07:30 am
csci
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
Medium
Report
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
8/27
07:30 am
csci
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
High
Report
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency